Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Protagonist Therapeutics Inc. (PTGX) Insider Trading Activity
Healthcare • Biotechnology • 125 employees
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Total Value
-$9,894,917.76
Total Shares
229,407
Average Trade Value
-$309,216.18
Most Active Insider
Gupta Suneel
Total Activity: $7,362,006
Largest Single Transaction
$4,762,239
by Gupta Suneel on Nov 25, 2024
30-Day Activity
1 Transaction
Volume: 24,000 shares
Value: $101,040
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President and CEO
Director, Officer
|
Mar 5, 2025 | 24,000 | $101,040 | 564,260 (+4.3%) | Exercise/Conversion | |
|
President and CEO
Director, Officer
|
Feb 19, 2025 | 5,359 | $204,607 | 540,260 (-1.0%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 16, 2025 | 388 | $10,000 | 87,144 (-0.4%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 16, 2025 | 3,252 | $10,000 | 83,892 (-3.9%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 16, 2025 | 2,601 | $10,000 | 62,821 (-4.1%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 16, 2025 | 1,317 | $10,000 | 65,422 (-2.0%) | Sale | |
|
President and CEO
Director, Officer
|
Jan 15, 2025 | 12,636 | $10,000 | 545,619 (-2.3%) | Payment of Exercise Price | |
|
Chief Medical Officer
Officer
|
Jan 2, 2025 | 41,088 | $0 | 87,532 (+46.9%) | Grant | |
|
Director
|
Jan 2, 2025 | 5,130 | $10,000 | 5,130 (+100.0%) | Grant | |
|
Director
|
Jan 2, 2025 | 5,130 | $10,000 | 5,130 (+100.0%) | Grant | |
|
Director
|
Jan 2, 2025 | 5,130 | $10,000 | 17,130 (+29.9%) | Grant | |
|
President and CEO
Director, Officer
|
Jan 2, 2025 | 149,800 | $0 | 558,255 (+26.8%) | Grant | |
|
Director
|
Jan 2, 2025 | 5,130 | $10,000 | 15,130 (+33.9%) | Grant | |
|
Director
|
Jan 2, 2025 | 5,130 | $10,000 | 33,126 (+15.5%) | Grant | |
|
Chief Financial Officer
Officer
|
Jan 2, 2025 | 31,779 | $0 | 66,739 (+47.6%) | Grant | |
|
Chief Medical Officer
Officer
|
Nov 27, 2024 | 10,000 | $445,000 | 46,444 (-21.5%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 27, 2024 | 16,000 | $717,280 | 46,444 (-34.5%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 27, 2024 | 16,000 | $128,640 | 62,444 (+25.6%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 27, 2024 | 10,000 | $80,400 | 56,444 (+17.7%) | Exercise/Conversion | |
|
Chief Development Officer
Officer
|
Nov 26, 2024 | 30,000 | $365,100 | 286,174 (+10.5%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 26, 2024 | 5,529 | $252,122 | 46,444 (-11.9%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 26, 2024 | 450 | $5,477 | 267,433 (+0.2%) | Exercise/Conversion | |
|
President and CEO
Director, Officer
|
Nov 26, 2024 | 21,480 | $993,450 | 408,455 (-5.3%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 26, 2024 | 5,529 | $44,453 | 51,973 (+10.6%) | Exercise/Conversion | |
|
Chief Development Officer
Officer
|
Nov 26, 2024 | 19,191 | $873,191 | 266,983 (-7.2%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 25, 2024 | 85,000 | $663,000 | 359,611 (+23.6%) | Exercise/Conversion | |
|
Chief Development Officer
Officer
|
Nov 25, 2024 | 103,437 | $4,762,239 | 256,174 (-40.4%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 25, 2024 | 45,000 | $360,900 | 274,611 (+16.4%) | Exercise/Conversion | |
|
President and CEO
Director, Officer
|
Nov 25, 2024 | 1,727 | $37,269 | 429,935 (+0.4%) | Exercise/Conversion | |
|
President and CEO
Director, Officer
|
Nov 25, 2024 | 78,520 | $3,687,299 | 435,208 (-18.0%) | Sale | |
|
Chief Development Officer
Officer
|
Nov 25, 2024 | 45,000 | $332,100 | 229,611 (+19.6%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 15, 2024 | 1,906 | $78,108 | 46,444 (-4.1%) | Sale |